Atezolizumab adjuvant therapy for treating renal cell carcinoma in people at high risk of developing metastasis following nephrectomy

Atezolizumab adjuvant therapy is in clinical development for renal cell carcinoma (RCC), which is
also called kidney cancer and affects the lining of tubes in the kidney. In many cases of renal cell
carcinoma there are no obvious symptoms at first and kidney cancer is found during tests for
another reason. For patients at increased risk of cancer returning and spreading (high‐risk RCC),
there is a ≥40% risk of recurrence after surgery (nephrectomy). Adjuvant treatment for RCC,
which is used to prevent cancer returning, has been an area of interest for clinicians to improve
disease‐free survival and overall survival in patients at high risk of recurrence.